Standout Papers
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial (2012)
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial (2012)
- VON RECKLINGHAUSEN NEUROFIBROMATOSIS (1988)
Immediate Impact
7 by Nobel laureates 14 from Science/Nature 111 standout
Citing Papers
Hallmarks of neurodegenerative diseases
2023 Standout
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
2021 StandoutScienceNobel
Works of D. A. S. Compston being referenced
Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement
1989 Nature
IMMUNOCYTOCHEMICAL LOCALIZATION OF THE TERMINAL COMPLEMENT COMPLEX IN MULTIPLE SCLEROSIS
1989
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| D. A. S. Compston | 7573 | 3467 | 2473 | 4215 | 179 | 13.3k | |
| Alasdair Coles | 8899 | 3735 | 2293 | 3232 | 193 | 13.1k | |
| Peter Rieckmann | 6616 | 3060 | 1733 | 2812 | 261 | 12.8k | |
| Bruce Cree | 8026 | 2658 | 2045 | 3431 | 275 | 12.5k | |
| Markus Reindl | 6391 | 2784 | 2435 | 6126 | 249 | 12.9k | |
| Christian Confavreux | 12473 | 3099 | 3740 | 4958 | 174 | 15.9k | |
| Robert P. Lisak | 4719 | 2605 | 1434 | 4409 | 304 | 11.7k | |
| Olaf Stüve | 6191 | 3303 | 1640 | 2543 | 248 | 11.2k | |
| Krzysztof Selmaj | 9341 | 5341 | 2625 | 3530 | 334 | 17.3k | |
| Gilles Edan | 13477 | 2362 | 3892 | 5398 | 144 | 16.1k | |
| Jeffrey L. Bennett | 7197 | 2161 | 2073 | 5568 | 174 | 10.2k |
All Works
Loading papers...